文献速递妇科

确定性盆腔放疗改善IVB期神经内分泌宫颈癌生存:一项NeCTuR研究

Definitive pelvic radiation therapy improves survival in stage IVB neuroendocrine cervical carcinoma: A NeCTuR study.
PubMed 文献 · Gynecol Oncol · 2022-04-05

该回顾性研究纳入1998-2020年诊断的71例FIGO 2018 IVB期神经内分泌宫颈癌患者,比较化疗联合或不联合确定性全盆腔放疗的生存结局。化疗联合放疗组的中位无进展生存期和总生存期均优于单纯化疗组,Cox回归显示确定性放疗与改善无进展生存期和总生存期相关。作者认为在化疗基础上加用确定性盆腔放疗可能改善此类患者的生存。

要点

  • 在IVB期神经内分泌宫颈癌患者中,化疗联合确定性盆腔放疗较单纯化疗与更长的无进展生存期和总生存期相关。
  • 化疗联合放疗组24个月无进展生存率为24%,单纯化疗组为7.8%;24个月总生存率分别为49.2%和21.5%。
  • Cox回归显示确定性放疗与改善无进展生存期(HR 0.44)和总生存期(HR 0.31)相关。

核心结论

  • 在IVB期神经内分泌宫颈癌患者中,在化疗基础上加用确定性盆腔放疗可能改善生存。

研究设计与样本

  • 回顾性研究纳入1998-2020年诊断的FIGO 2018 IVB期神经内分泌宫颈癌患者71例,接受化疗联合或不联合确定性全盆腔放疗(同期或序贯)。
  • 56例(79%)接受单纯化疗(其中15例联合姑息性盆腔放疗,41例未联合),15例(21%)接受化疗联合确定性盆腔放疗。
  • 采用Kaplan-Meier法绘制生存曲线,Cox回归计算风险比(HR)。

主要发现

  • 中位年龄43岁(范围24-75岁);59例(83%)为纯神经内分泌组织学;57例(80%)治疗前肿瘤大小>4 cm。
  • 化疗联合放疗组中位随访20.1个月(范围11.3-170.3),单纯化疗组中位随访13.5个月(范围0.9-73.6)。
  • 化疗联合放疗组中位无进展生存期10.3个月(95% CI 7.5-∞) vs 单纯化疗组6.6个月(95% CI 6.1-8.7),p=0.0097;24个月无进展生存率分别为24%和7.8%。
  • 化疗联合放疗组中位总生存期20.3个月(95% CI 18.5-∞) vs 单纯化疗组13.6个月(95% CI 11.3-19.2),p=0.0013;24个月总生存率分别为49.2%和21.5%。
  • Cox回归中,确定性放疗与改善无进展生存期相关(HR 0.44;95% CI 0.23-0.83;p=0.0119),与改善总生存期相关(HR 0.31;95% CI 0.14-0.65;p=0.0022)。

临床怎么用

  • 作者认为,在IVB期神经内分泌宫颈癌患者中,在化疗基础上加用确定性盆腔放疗可能改善生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the survival impact of adding definitive pelvic radiation therapy (RT) to chemotherapy among patients with stage IVB neuroendocrine cervical carcinoma (NECC). METHODS: We retrospectively studied patients with FIGO 2018 stage IVB NECC diagnosed during 1998-2020 who received chemotherapy with or without definitive whole pelvic RT (concurrent or sequential). Demographic, oncologic, and treatment characteristics were summarized. Progression-free (PFS) and overall survival (OS) were plotted using the Kaplan-Meier method, and hazard ratios (HRs) were calculated using Cox regression. RESULTS: The study included 71 patients. Median age was 43 years (range, 24-75). Fifty-nine patients (83%) had pure neuroendocrine histology, and 57 (80%) had pretreatment tumor size >4 cm. Fifty-six patients (79%) received chemotherapy alone with (n = 15) or without (n = 41) palliative pelvic RT, and 15 (21%) received chemotherapy and definitive pelvic RT (chemo+RT). Median follow-up time was 20.1 months (range, 11.3-170.3) for the chemo+RT group and 13.5 months (range, 0.9-73.6) for the chemotherapy-alone group. Median PFS was 10.3 months (95% CI, 7.5-∞) for the chemo+RT group vs 6.6 months (95% CI, 6.1-8.7) for the chemotherapy-alone group (p = 0.0097). At 24 months, the PFS rate was 24% for chemo+RT vs 7.8% for chemotherapy alone. Median OS was 20.3 months (95% CI, 18.5-∞) for the chemo+RT group vs 13.6 months (95% CI, 11.3-19.2) for the chemotherapy-alone group (p = 0.0013). At 24 months, the OS rate was 49.2% for chemo+RT vs 21.5% for chemotherapy alone. In a Cox regression model, definitive RT was associated with improved PFS (HR, 0.44; 95% CI, 0.23-0.83; p = 0.0119) and OS (HR, 0.31; 95% CI, 0.14-0.65; p = 0.0022). CONCLUSIONS: Addition of definitive pelvic RT to chemotherapy may improve survival in patients with stage IVB NECC.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Salvo G, Jhingran A, Ramalingam P, et al. Definitive pelvic radiation therapy improves survival in stage IVB neuroendocrine cervical carcinoma: A NeCTuR study. Gynecol Oncol. 2022. PMID: 35396134. doi:10.1016/j.ygyno.2022.03.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。